Case report: Alpelisib-induced Stevens–Johnson syndrome
BackgroundAlpelisib is a recently approved treatment for hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer. It has been associated with alopecia and rash, but there are no documented cases of Stevens–Johnson Syndrome (SJS) associated with this drug. Here, we detail the...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.954027/full |
| _version_ | 1811208549439635456 |
|---|---|
| author | Christine Jane Kurian Akshay Desai William Rafferty Ahmed Kamel Abou Hussein |
| author_facet | Christine Jane Kurian Akshay Desai William Rafferty Ahmed Kamel Abou Hussein |
| author_sort | Christine Jane Kurian |
| collection | DOAJ |
| description | BackgroundAlpelisib is a recently approved treatment for hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer. It has been associated with alopecia and rash, but there are no documented cases of Stevens–Johnson Syndrome (SJS) associated with this drug. Here, we detail the first case of SJS associated with alpelisib.Case descriptionOur patient is a 60-year-old woman with a past medical history of metastatic hormone receptor-positive (ER+ 80% and PR+ 1%), HER2-negative metastatic breast cancer who presented with acute odynophagia, fevers, and diffuse body rash after receiving her first doses of alpelisib and fulvestrant in the preceding days. She presented to the emergency department after developing a whole-body rash and severe ulceration of her buccal mucosa. She was started on methylprednisolone with remarkable improvement in symptoms.ConclusionThis case report details the only report of SJS following alpelisib treatment. Immediate cessation of drugs and initiation of steroids are the cornerstone of treatment. Patients who experience such side effects will have to be monitored closely for long-term sequelae associated with SJS, including cutaneous, ocular, and oral sequelae, all of which can profoundly affect the quality of life for cancer patients. |
| first_indexed | 2024-04-12T04:23:15Z |
| format | Article |
| id | doaj.art-6bff6cbde2e74beb96c34b5908173a67 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-12T04:23:15Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-6bff6cbde2e74beb96c34b5908173a672022-12-22T03:48:09ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-09-011210.3389/fonc.2022.954027954027Case report: Alpelisib-induced Stevens–Johnson syndromeChristine Jane Kurian0Akshay Desai1William Rafferty2Ahmed Kamel Abou Hussein3Department of Hematology and Medical Oncology, MD Anderson Cancer Center at Cooper University Healthcare, Camden, NJ, United StatesDepartment of Internal Medicine, Cooper University Healthcare, Camden, NJ, United StatesDepartment of Pathology, Cooper University Healthcare, Camden, NJ, United StatesDepartment of Hematology and Medical Oncology, MD Anderson Cancer Center at Cooper University Healthcare, Camden, NJ, United StatesBackgroundAlpelisib is a recently approved treatment for hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer. It has been associated with alopecia and rash, but there are no documented cases of Stevens–Johnson Syndrome (SJS) associated with this drug. Here, we detail the first case of SJS associated with alpelisib.Case descriptionOur patient is a 60-year-old woman with a past medical history of metastatic hormone receptor-positive (ER+ 80% and PR+ 1%), HER2-negative metastatic breast cancer who presented with acute odynophagia, fevers, and diffuse body rash after receiving her first doses of alpelisib and fulvestrant in the preceding days. She presented to the emergency department after developing a whole-body rash and severe ulceration of her buccal mucosa. She was started on methylprednisolone with remarkable improvement in symptoms.ConclusionThis case report details the only report of SJS following alpelisib treatment. Immediate cessation of drugs and initiation of steroids are the cornerstone of treatment. Patients who experience such side effects will have to be monitored closely for long-term sequelae associated with SJS, including cutaneous, ocular, and oral sequelae, all of which can profoundly affect the quality of life for cancer patients.https://www.frontiersin.org/articles/10.3389/fonc.2022.954027/fullbreast cancermetastatic breast canceralpelisibStevens Johnson syndrome (SJS)Stevens Johnson Syndrome |
| spellingShingle | Christine Jane Kurian Akshay Desai William Rafferty Ahmed Kamel Abou Hussein Case report: Alpelisib-induced Stevens–Johnson syndrome Frontiers in Oncology breast cancer metastatic breast cancer alpelisib Stevens Johnson syndrome (SJS) Stevens Johnson Syndrome |
| title | Case report: Alpelisib-induced Stevens–Johnson syndrome |
| title_full | Case report: Alpelisib-induced Stevens–Johnson syndrome |
| title_fullStr | Case report: Alpelisib-induced Stevens–Johnson syndrome |
| title_full_unstemmed | Case report: Alpelisib-induced Stevens–Johnson syndrome |
| title_short | Case report: Alpelisib-induced Stevens–Johnson syndrome |
| title_sort | case report alpelisib induced stevens johnson syndrome |
| topic | breast cancer metastatic breast cancer alpelisib Stevens Johnson syndrome (SJS) Stevens Johnson Syndrome |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.954027/full |
| work_keys_str_mv | AT christinejanekurian casereportalpelisibinducedstevensjohnsonsyndrome AT akshaydesai casereportalpelisibinducedstevensjohnsonsyndrome AT williamrafferty casereportalpelisibinducedstevensjohnsonsyndrome AT ahmedkamelabouhussein casereportalpelisibinducedstevensjohnsonsyndrome |